EXELON
LOE ApproachingNDAORALCAPSULE
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
EXELON by Novartis is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. Approved for dementia of the alzheimer’s type (ad), mild-to-moderate dementia associated with parkinson’s disease (pdd). First approved in 2000.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXELON (rivastigmine) is an oral small-molecule capsule approved in 2000 for treating dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease. It works by reversibly inhibiting cholinesterase to increase acetylcholine concentration in the brain, thereby enhancing cholinergic function. The drug does not alter the underlying disease course and its efficacy may diminish as disease progresses and fewer cholinergic neurons remain intact. It represents a standard-of-care cholinesterase inhibitor option in the cognitive disorder treatment landscape.
$0.0BPart D
Mechanism of Action
unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances…
Worked on EXELON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.